Tirofiban influences serum inflammatory factors and neurotransmitter levels in acute cerebral infarction patients

This study investigated the effects of tirofiban on serum inflammatory factors and neurotransmitter levels in 122 patients with acute cerebral infarction (ACI) at a Nigerian teaching hospital from January 2021 to December 2023. Patients were divided into conventional and study groups, with the study group receiving tirofiban in addition to standard treatment. Clinical efficacy and levels of Interleukin 6 (IL-6), serum tumor necrosis factor (TNF-α), 5-hydroxytryptamine (5-HT), dopamine (DA), and glutamic acid (Glu) were compared. Result findings showed that the research group (RG) had a significantly higher total effective rate of treatment (93.44%) compared to the conventional group. While IL-6 and TNF-α levels were similar between groups initially and at 7 days post-treatment, they were lower in the study group at 14 days post-treatment. Levels of 5-HT, DA, and Glu did not differ initially and at 7 days post-treatment but were higher in the study group at 14 days for 5-HT and DA, while Glu was lower. In conclusion, tirofiban improved clinical efficacy, reduce serum inflammatory responses, and impact neurotransmitter levels in patients with ACI.